Prevalence of antiphospholipid antibodies among patients with chronic thromboembolic pulmonary hypertension
In most cases of acute pulmonary embolism, fibrinolysis of the embolus takes place, restoring blood flow and normalizing hemodynamic parameters. However, in a minority of patients, a residual organized clot remains adherent to the pulmonary vasculature which, over time, results in a progressive increase in pulmonary vascular resistance. This condition, known as chronic thromboembolic pulmonary hypertension (CTEPH), is a rare complication of pulmonary embolism that is characterized by the presence of persistent and organized thrombi in the proximal pulmonary arteries [1, 2]. Poor thrombus resolution due to inadequate fibrinolysis and/or recurrent thrombosis likely predispose towards the development of CTEPH. However, why only a small subset of patients go on to develop CTEPH following acute pulmonary embolism remains uncertain.
The classic hereditary thrombophilias, namely deficiencies in antithrombin, protein C and S, provide a plausible biologic basis for pulmonary vascular thrombus...
Compliance with ethical standards
Conflict of interest
Dr. Douketis reports receiving consulting fees or honouraria from Janssen, Pfizer, Sanofi, and Leo Pharma.
Statement on human and animal rights
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent is not required for this type of study.